echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Mechanism of action of baricitinib in patients with active systemic lupus erythematosus and identification of biomarkers and key immune pathways

    ARD: Mechanism of action of baricitinib in patients with active systemic lupus erythematosus and identification of biomarkers and key immune pathways

    • Last Update: 2022-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE : To elucidate the mechanism of action of baricitinib , a Janus kinase (JAK) 1/2 inhibitor , and to describe disease activity-related disease activity in adult patients with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II tri.


    OBJECTIVE: To elucidate the mechanism of action of baricitinib , a Janus kinase (JAK) 1/2 inhibitor , and to characterize disease activity-related immunity in adult patients with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II tri.


    Methods : In a phase II randomized, placebo-controlled study, patients with SLE received either 2mg or 4 mg of baricitini.


    Methods In a phase II randomized, placebo-controlled study, patients with SLE received either 2 mg or 4 mg of baricitini.


    Results At baseline, SLE sera had marked cytokine dysregulation relative to HC ser.


    Conclusions: These results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in SLE patients and may play a role in a multi-target mechanism beyond the IFN signature, although the clinical relevance remains to be further describe.


    Dörner T, Tanaka Y, Dow ER , et a.
    Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematos.
    Annals of the Rheumatic DiseasesPublished Online First: 24 May 202 doi: 11136/ annrheumdis-2022-222335 , et al Annals of the Rheumatic Diseasesleave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.